Chengdu Kanghong Pharmaceutical Co. Ltd. has disclosed new compounds targeting apolipoprotein A (ApoA; LPA) and acting as lipoprotein(a)-lowering agents that are potentially useful for the treatment of cardiovascular disorders.

Emory University has divulged new prostaglandin EP2 receptor (PTGER2) antagonists potentially useful for the treatment of cancer, neuropathic pain, hypertension, inflammatory bowel disease, Alzheimer’s disease, atherosclerosis, asthma and glomerulonephritis, among others.

Suzhou Spring-Sea Bio-Pharmaceuticals Co. Ltd. has discovered new prodrugs of glucagon-like peptide 1 (GLP-1) polypeptides acting as glucagon-like peptide 1 receptor (GLP-1R) agonists reported to be useful for the treatment of diabetes, obesity, overweight, chronic kidney disease, metabolic dysfunction-associated steatotic liver disease, neurodegeneration, diabetic nephropathy and cardiovascular disorders, among others.

Vertex Pharmaceuticals Inc. has patented new macrocyclic sulfonamide orexin OX2 receptor agonists potentially useful for the treatment of amyotrophic lateral sclerosis, obesity, hypertension, retinopathy, multiple sclerosis, narcolepsy, hypersomnia and Parkinson's disease, among others.

Acadia Pharmaceuticals Inc. has reported new G protein-coupled receptor GPR88 agonists that are potentially useful for the treatment of tardive dyskinesia.

Amgen Inc. has patented new GTPase KRAS (mutant) inhibitors, particularly, GTPase KRAS (G12D mutant) inhibitors that are potentially useful for the treatment of cancer.

Ocean University of China has discovered new androgen receptor N-terminal domain (AR-NTD) inhibitors reported to be useful for the treatment of prostate cancer.

Wuhan Xirui Pharmaceutical Technology Co. Ltd. has synthesized new amphotericin B amide derivatives that are potentially useful for the treatment of fungal infection.

Researchers from Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have patented new sodium channel protein type 10 subunit α (SCN10A; Nav1.8) blockers that are potentially useful for the treatment of pain, urinary incontinence, multiple sclerosis, cough and arrhythmia.

Biocad Ltd. has disclosed new antibody-drug conjugates consisting of antibodies covalently linked to cytotoxic drugs through linkers reported to be useful for the treatment of cancer.